4basebio (LON:4BB) Stock Price Down 4.1% – What’s Next?

4basebio PLC (LON:4BB)’s share price was down 4.1% on Friday . The company traded as low as GBX 1,180 ($14.73) and last traded at GBX 1,180 ($14.73). Approximately 12 shares changed hands during mid-day trading, a decline of 98% from the average daily volume of 618 shares. The stock had previously closed at GBX 1,230 ($15.35).

4basebio Trading Down 4.1 %

The business’s fifty day simple moving average is GBX 1,228.32 and its two-hundred day simple moving average is GBX 1,333.83. The company has a market cap of £151.16 million, a price-to-earnings ratio of -1,512.82 and a beta of 1.09. The company has a quick ratio of 3.52, a current ratio of 2.73 and a debt-to-equity ratio of 201.47.

Insiders Place Their Bets

In related news, insider Heikki Lanckriet purchased 46,500 shares of the company’s stock in a transaction dated Friday, November 15th. The shares were acquired at an average cost of GBX 1,325 ($16.54) per share, for a total transaction of £616,125 ($769,098.74). 68.44% of the stock is currently owned by corporate insiders.

4basebio Company Profile

4basebio is a specialist life sciences group focused on supplying therapeutic synthetic DNA for gene therapies and gene-based vaccines and providing solutions for effective and safe delivery of DNA/RNA based products to patients.

Our focus is the development of high quality, GMP grade synthetic DNA as well as non-viral nanoparticles which can efficiently and safely deliver fully functional genes to patients.